1	Food	_	NNP	_	_	8	SBJ	_	_
2	and	_	CC	_	_	1	COORD	_	_
3	Drug	_	NNP	_	_	7	NAME	_	_
4	Administration	_	NNP	_	_	7	NAME	_	_
5	spokesman	_	NN	_	_	7	NMOD	_	_
6	Jeff	_	NNP	_	_	7	NAME	_	_
7	Nesbit	_	NNP	_	_	2	CONJ	_	_
8	said	_	VBD	_	_	0	ROOT	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	agency	_	NN	_	_	11	SBJ	_	_
11	has	_	VBZ	_	_	8	OBJ	_	_
12	turned	_	VBN	_	_	11	VC	_	_
13	over	_	RP	_	_	12	PRT	_	_
14	evidence	_	NN	_	_	12	OBJ	_	_
15	in	_	IN	_	_	12	LOC	_	_
16	a	_	DT	_	_	18	NMOD	_	_
17	criminal	_	JJ	_	_	18	NMOD	_	_
18	investigation	_	NN	_	_	15	PMOD	_	_
19	concerning	_	VBG	_	_	18	APPO	_	_
20	Vitarine	_	NNP	_	_	21	NAME	_	_
21	Pharmaceuticals	_	NNP	_	_	19	OBJ	_	_
22	Inc.	_	NNP	_	_	21	POSTHON	_	_
23	to	_	TO	_	_	12	ADV	_	_
24	the	_	DT	_	_	26	NMOD	_	_
25	U.S.	_	NNP	_	_	26	NAME	_	_
26	Attorney	_	NNP	_	_	28	NMOD	_	_
27	's	_	POS	_	_	26	SUFFIX	_	_
28	office	_	NN	_	_	23	PMOD	_	_
29	in	_	IN	_	_	28	LOC	_	_
30	Baltimore	_	NNP	_	_	29	PMOD	_	_
31	.	_	.	_	_	8	P	_	_

1	Neither	_	DT	_	_	2	NMOD	_	_
2	Vitarine	_	NNP	_	_	17	SBJ	_	_
3	nor	_	CC	_	_	2	COORD	_	_
4	any	_	DT	_	_	3	CONJ	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	12	NMOD	_	_
7	Springfield	_	NNP	_	_	10	NAME	_	_
8	Gardens	_	NNP	_	_	10	NAME	_	_
9	,	_	,	_	_	10	P	_	_
10	N.Y.	_	NNP	_	_	12	LOC	_	_
11	,	_	,	_	_	10	P	_	_
12	company	_	NN	_	_	14	NMOD	_	_
13	's	_	POS	_	_	12	SUFFIX	_	_
14	officials	_	NNS	_	_	5	PMOD	_	_
15	or	_	CC	_	_	14	COORD	_	_
16	employees	_	NNS	_	_	15	CONJ	_	_
17	have	_	VBP	_	_	0	ROOT	_	_
18	been	_	VBN	_	_	17	VC	_	_
19	charged	_	VBN	_	_	18	VC	_	_
20	with	_	IN	_	_	19	ADV	_	_
21	any	_	DT	_	_	22	NMOD	_	_
22	crimes	_	NNS	_	_	20	PMOD	_	_
23	.	_	.	_	_	17	P	_	_

1	Vitarine	_	NNP	_	_	2	SBJ	_	_
2	won	_	VBD	_	_	0	ROOT	_	_
3	approval	_	NN	_	_	2	OBJ	_	_
4	to	_	TO	_	_	3	NMOD	_	_
5	market	_	VB	_	_	4	IM	_	_
6	a	_	DT	_	_	7	NMOD	_	_
7	version	_	NN	_	_	5	OBJ	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	a	_	DT	_	_	12	NMOD	_	_
10	blood	_	NN	_	_	12	NMOD	_	_
11	pressure	_	NN	_	_	12	NMOD	_	_
12	medicine	_	NN	_	_	8	PMOD	_	_
13	but	_	CC	_	_	2	COORD	_	_
14	acknowledged	_	VBD	_	_	13	CONJ	_	_
15	that	_	IN	_	_	14	OBJ	_	_
16	it	_	PRP	_	_	17	SBJ	_	_
17	substituted	_	VBD	_	_	15	SUB	_	_
18	a	_	DT	_	_	22	NMOD	_	_
19	SmithKline	_	NNP	_	_	22	NMOD	_	_
20	Beecham	_	NNP	_	_	22	NMOD	_	_
21	PLC	_	NNP	_	_	22	NMOD	_	_
22	product	_	NN	_	_	17	OBJ	_	_
23	as	_	IN	_	_	17	ADV	_	_
24	its	_	PRP$	_	_	25	NMOD	_	_
25	own	_	JJ	_	_	23	PMOD	_	_
26	in	_	IN	_	_	17	LOC	_	_
27	tests	_	NNS	_	_	26	PMOD	_	_
28	.	_	.	_	_	2	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Nesbit	_	NNP	_	_	4	SBJ	_	_
3	also	_	RB	_	_	4	ADV	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	FDA	_	NNP	_	_	7	SBJ	_	_
7	has	_	VBZ	_	_	4	OBJ	_	_
8	asked	_	VBN	_	_	7	VC	_	_
9	Bolar	_	NNP	_	_	10	NAME	_	_
10	Pharmaceutical	_	NNP	_	_	8	OBJ	_	_
11	Co.	_	NNP	_	_	10	POSTHON	_	_
12	to	_	TO	_	_	8	OPRD	_	_
13	recall	_	VB	_	_	12	IM	_	_
14	at	_	IN	_	_	13	LOC	_	_
15	the	_	DT	_	_	17	NMOD	_	_
16	retail	_	JJ	_	_	17	NMOD	_	_
17	level	_	NN	_	_	14	PMOD	_	_
18	its	_	PRP$	_	_	21	NMOD	_	_
19	urinary	_	JJ	_	_	21	NMOD	_	_
20	tract	_	NN	_	_	21	NMOD	_	_
21	antibiotic	_	NN	_	_	13	OBJ	_	_
22	.	_	.	_	_	4	P	_	_

1	But	_	CC	_	_	6	DEP	_	_
2	so	_	RB	_	_	6	TMP	_	_
3	far	_	RB	_	_	2	AMOD	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	company	_	NN	_	_	6	SBJ	_	_
6	has	_	VBZ	_	_	15	OBJ	_	_
7	n't	_	RB	_	_	6	ADV	_	_
8	complied	_	VBN	_	_	6	VC	_	_
9	with	_	IN	_	_	8	ADV	_	_
10	that	_	DT	_	_	11	NMOD	_	_
11	request	_	NN	_	_	9	PMOD	_	_
12	,	_	,	_	_	15	P	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	spokesman	_	NN	_	_	15	SBJ	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	.	_	.	_	_	15	P	_	_

1	Bolar	_	NNP	_	_	27	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	subject	_	NN	_	_	1	APPO	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	a	_	DT	_	_	8	NMOD	_	_
7	criminal	_	JJ	_	_	8	NMOD	_	_
8	investigation	_	NN	_	_	5	PMOD	_	_
9	by	_	IN	_	_	8	NMOD	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	FDA	_	NNP	_	_	9	PMOD	_	_
12	and	_	CC	_	_	11	COORD	_	_
13	the	_	DT	_	_	15	NMOD	_	_
14	Inspector	_	NNP	_	_	15	NAME	_	_
15	General	_	NNP	_	_	17	NMOD	_	_
16	's	_	POS	_	_	15	SUFFIX	_	_
17	office	_	NN	_	_	12	CONJ	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	Health	_	NNP	_	_	18	PMOD	_	_
21	and	_	CC	_	_	20	COORD	_	_
22	Human	_	NNP	_	_	24	NAME	_	_
23	Services	_	NNP	_	_	24	NAME	_	_
24	Department	_	NNP	_	_	21	CONJ	_	_
25	,	_	,	_	_	1	P	_	_
26	only	_	RB	_	_	27	ADV	_	_
27	agreed	_	VBD	_	_	51	OBJ	_	_
28	to	_	TO	_	_	27	OPRD	_	_
29	recall	_	VB	_	_	28	IM	_	_
30	two	_	CD	_	_	31	NMOD	_	_
31	strengths	_	NNS	_	_	29	OBJ	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	its	_	PRP$	_	_	34	NMOD	_	_
34	version	_	NN	_	_	32	PMOD	_	_
35	of	_	IN	_	_	34	NMOD	_	_
36	Macrodantin	_	NNP	_	_	35	PMOD	_	_
37	``	_	``	_	_	29	P	_	_
38	as	_	RB	_	_	29	ADV	_	_
39	far	_	RB	_	_	38	AMOD	_	_
40	down	_	RB	_	_	38	AMOD	_	_
41	as	_	IN	_	_	38	AMOD	_	_
42	direct	_	JJ	_	_	43	NMOD	_	_
43	customers	_	NNS	_	_	41	PMOD	_	_
44	,	_	,	_	_	43	P	_	_
45	mostly	_	RB	_	_	43	NMOD	_	_
46	wholesalers	_	NNS	_	_	43	APPO	_	_
47	,	_	,	_	_	51	P	_	_
48	''	_	''	_	_	51	P	_	_
49	Mr.	_	NNP	_	_	50	TITLE	_	_
50	Nesbit	_	NNP	_	_	51	SBJ	_	_
51	said	_	VBD	_	_	0	ROOT	_	_
52	.	_	.	_	_	51	P	_	_

1	Bolar	_	NNP	_	_	9	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	of	_	IN	_	_	1	NMOD	_	_
4	Copiague	_	NNP	_	_	3	PMOD	_	_
5	,	_	,	_	_	4	P	_	_
6	N.Y.	_	NNP	_	_	4	APPO	_	_
7	,	_	,	_	_	4	P	_	_
8	earlier	_	RBR	_	_	9	TMP	_	_
9	began	_	VBD	_	_	0	ROOT	_	_
10	a	_	DT	_	_	12	NMOD	_	_
11	voluntary	_	JJ	_	_	12	NMOD	_	_
12	recall	_	NN	_	_	9	OBJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	both	_	DT	_	_	21	NMOD	_	_
15	its	_	PRP$	_	_	21	NMOD	_	_
16	100	_	CD	_	_	17	AMOD	_	_
17	milligram	_	NN	_	_	21	NMOD	_	_
18	and	_	CC	_	_	17	COORD	_	_
19	50	_	CD	_	_	20	AMOD	_	_
20	milligram	_	NN	_	_	18	CONJ	_	_
21	versions	_	NNS	_	_	13	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	drug	_	NN	_	_	22	PMOD	_	_
25	.	_	.	_	_	9	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	FDA	_	NNP	_	_	3	SBJ	_	_
3	has	_	VBZ	_	_	0	ROOT	_	_
4	said	_	VBD	_	_	3	VC	_	_
5	it	_	PRP	_	_	6	SBJ	_	_
6	presented	_	VBD	_	_	4	OBJ	_	_
7	evidence	_	NN	_	_	6	OBJ	_	_
8	it	_	PRP	_	_	9	SBJ	_	_
9	uncovered	_	VBD	_	_	7	NMOD	_	_
10	to	_	TO	_	_	6	ADV	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	company	_	NN	_	_	10	PMOD	_	_
13	indicating	_	VBG	_	_	7	APPO	_	_
14	that	_	IN	_	_	13	OBJ	_	_
15	Bolar	_	NNP	_	_	16	SBJ	_	_
16	substituted	_	VBD	_	_	14	SUB	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	brand-name	_	JJ	_	_	19	NMOD	_	_
19	product	_	NN	_	_	16	OBJ	_	_
20	for	_	IN	_	_	16	ADV	_	_
21	its	_	PRP$	_	_	22	NMOD	_	_
22	own	_	JJ	_	_	20	PMOD	_	_
23	to	_	TO	_	_	16	PRP	_	_
24	gain	_	VB	_	_	23	IM	_	_
25	government	_	NN	_	_	26	NMOD	_	_
26	approval	_	NN	_	_	24	OBJ	_	_
27	to	_	TO	_	_	26	NMOD	_	_
28	sell	_	VB	_	_	27	IM	_	_
29	generic	_	JJ	_	_	30	NMOD	_	_
30	versions	_	NNS	_	_	28	OBJ	_	_
31	of	_	IN	_	_	30	NMOD	_	_
32	Macrodantin	_	NNP	_	_	31	PMOD	_	_
33	.	_	.	_	_	3	P	_	_

1	Bolar	_	NNP	_	_	2	SBJ	_	_
2	has	_	VBZ	_	_	0	ROOT	_	_
3	denied	_	VBN	_	_	2	VC	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	it	_	PRP	_	_	6	SBJ	_	_
6	switched	_	VBD	_	_	4	SUB	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	brand-name	_	JJ	_	_	9	NMOD	_	_
9	product	_	NN	_	_	6	OBJ	_	_
10	for	_	IN	_	_	6	ADV	_	_
11	its	_	PRP$	_	_	12	NMOD	_	_
12	own	_	JJ	_	_	10	PMOD	_	_
13	in	_	IN	_	_	6	LOC	_	_
14	such	_	JJ	_	_	15	NMOD	_	_
15	testing	_	NN	_	_	13	PMOD	_	_
16	.	_	.	_	_	2	P	_	_

